Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple perfusions for melanoma

E T Krementz1, J H Muchmore, R D Carter

  • 1Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112.

Melanoma Research
|March 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.

Breast cancer research : BCR·2022
Same author

Physician assistants. A young profession celebrates the 35th anniversary of its birth in North Carolina.

North Carolina medical journal·2000
Same author

Intra-arterial chemotherapy for unresectable pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2000
Same author

Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1998
Same author

Isolated hyperthermia chemotherapy perfusion for limb melanoma.

The Surgical clinics of North America·1996
Same author

Malignant melanoma in American black females: an unusual distribution of primary sites.

Journal of the American College of Surgeons·1996
Same journal

The role of circulating tumor DNA in the management of melanoma: a literature review.

Melanoma research·2026
Same journal

Schisandrin C suppresses melanoma growth and metastasis through modulation of Rap1-related and phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin signaling pathways.

Melanoma research·2026
Same journal

Factors to consider in a primary care setting when using convolutional neural network tools for melanoma diagnostics: a retrospective analysis of images and patient characteristics.

Melanoma research·2026
Same journal

Melanocortin-1 receptor variants and telomerase reverse transcriptase promoter mutations as prognostic biomarkers in stage IIB-IIC melanoma.

Melanoma research·2026
Same journal

Twenty-one years of cutaneous melanoma: stage shift, anatomical patterns and diagnostic trends from a Southern European tertiary center.

Melanoma research·2026
Same journal

Meaningful efficacy measures and trial endpoints in patients with advanced melanoma being considered for adjuvant systemic therapy: a prospective patient survey study.

Melanoma research·2026
See all related articles

Regional perfusion therapy for malignant melanoma showed limited survival benefits compared to the entire series. However, 21 patients achieved long-term disease-free survival, particularly in earlier stages.

Area of Science:

  • Oncology
  • Surgical Oncology
  • Medical Oncology

Background:

  • Malignant melanoma treatment has evolved, with regional perfusion being a historical approach.
  • Recurrent melanoma, especially in limbs and head/neck regions, presents treatment challenges.

Purpose of the Study:

  • To evaluate the long-term outcomes of regional perfusion therapy for malignant melanoma.
  • To assess survival rates and disease-free status in patients treated with regional perfusion.

Main Methods:

  • Retrospective analysis of 1139 patients treated between 1957 and 1992.
  • Regional perfusion, alone or with surgery, using agents like Melphalan.
  • Analysis of survival data stratified by disease stage (I-IV) and number of perfusions.

Related Experiment Videos

Main Results:

  • Cumulative 5 and 10-year survival rates varied significantly by stage, with Stage IV showing 14% and 0% survival, respectively.
  • Despite lower overall survival compared to the entire series, 21 patients achieved disease-free survival.
  • Long-term disease-free survival (5-33 years) was observed in Stages I and II; specific cases of long-term survival were noted in Stages IIIA, IIIB, and IIIAB.

Conclusions:

  • Regional perfusion therapy for malignant melanoma demonstrated a survival benefit in a subset of patients, particularly those with earlier stage disease.
  • While overall survival rates were reduced, the therapy offered a chance for long-term remission in select cases.
  • The study highlights the historical use and variable outcomes of regional perfusion in melanoma management.